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Summary--Pharmacokinetics of 4-hydroxyandrostenedione (4-OHA), a potent aromatase 
inhibitor under investigation for treatment of postmenopausal breast cancer, were studied 
using two formulations with different particle sizes of 4.2 and 8.0 #m, respectively. A single 
250 mg dose of 4-OHA of each of the two formulations was administered in two different 
periods to six healthy male volunteers and blood samples were collected for up to 14 days. 
4-OHA plasma levels were determined using the isotope dilution mass spectrometry method. 
Comparison of the pharmacokinetic profiles of the two formulations did not show any 
statistically significant difference, even though the 4.2 pm particle size gave apparently higher 
levels at 24 h. Using this formulation, the effects of 4-OHA on the plasma levels of 
aromatizable androgens (testosterone and androstenedione) and 17fl-estradiol were studied. 
An isotope dilution mass spectrometry method was developed for the simultaneous quantitat- 
ive determination f these steroids in human plasma. The analysis of plasma samples howed 
a significant reduction of plasma estradiol concentrations (50%) which coincided with the 
maximum concentration peak of the inhibitor, whereas no significant changes in androgen 
levels were observed. 
INTRODUCTION 
4-Hydroxy-4-androstene-3,17-dione (4-OHA), a 
potent aromatase inhibitor, has been under 
investigation for treatment of postmenopausal 
breast cancer for the last few years [1, 2]. More 
recently aromatase inhibitors have also been 
proposed for treatment of human benign pro- 
static hypertrophy (BPH) [4, 5]. The kinetics of 
these drugs in human male plasma are thus of 
clinical interest. 
Unlike some non-steroidal aromatase inhibi- 
tors, 4-OHA does not have any relevant effect 
on adrenal steroidogenesis [6]. When adminis- 
tered to postmenopausal women, the compound 
is without significant side effects except for 
occasional sterile abscesses at the injection 
site [I]. This is thought o be due to local effects 
of the steroidal material. The evaluation of the 
optimal particle size which can realize the 
highest plasma concentrations of the drug 
*To whom correspondence should be addressed. 
versus the lowest incidence of side effects is, 
therefore, of clinical relevance. The injected 
dose should also be important and consequently 
during the last years the initial dose of 500 mg 
every 2 weeks was reduced to 250 mg [6]. 
In this paper we report the pharmacokinetics 
of two different formulations of 4-OHA with 
different particle size (4.2 and 8.0 #m) injected 
as a 250 mg dose in six healthy male volunteers. 
Quantitative determinations of 4-OHA plasma 
levels were obtained using an isotope dilution 
GC/MS method. In addition the effects on 
circulating aromatizable androgens (testoster- 
one, androstenedione) and 17fl-estradiol (E2) 
were studied using the formulation which gave 
the highest concentration of 4-OHA. 
EXPERIMENTAL 
Materials 
4-OHA was provided by Ciba-Geigy 
Medical Department, (Origgio, Varese, Italy). 
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Testosterone, androstenedione and E 2 were pur- 
chased from Sigma. Deuterated standards were 
previously synthesized in our laboratories [7, 8]. 
Solvents of analytical grade were purchased 
from Carlo Erba. 
Extrelut columns were obtained from 
Merck. Sephadex-LH-20 was purchased from 
Pharmacia. N, O-bis(trimethylsilyl)-trifluoroac- 
etamide (BSTFA), pentafluoropropionic anhy- 
dride (PFPA), heptafluorobutyric anhydride 
(HFBA), and trimethylsilylchloride (TMSC1) 
were obtained from Fluka. 
All analyses were performed using a Hewlett- 
Packard GC/MS system composed of a 5890 
series II gas-chromatograph equipped with a 
5971A Mass Spectrometry Detector and a 
7673A automatic injector. 
Methods 
Blood samples 
Two different formulations of 4-OHA (par- 
ticle size 4.2 and 8.0/~ m) were injected intramus- 
cularly as a single dose of 250 mg in 6 healthy 
male volunteers aged 20 to 45 years. Blood 
samples were collected before (time point 0) and 
4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 96, 168, 240 
and 336 h after each intramuscular injection. 
There was a wash-out phase of at least 4 week 
duration between the administration f the two 
formulations. Immediately after collection the 
samples were centrifuged and plasma was stored 
at - 20°C in two aliquots of 2 ml until analysis. 
4-OHA determination 
4-OHA concentrations were determined using 
the isotope dilution mass spectrometry method 
described previously by us [3]. The internal stan- 
dard was 7,712HL4-OHA (D2-4-OHA). 
Standard solutions. Ethanol solutions of 4- 
OHA and its deuterated standard were used at 
the following concentrations (pg/#l): D2-4- 
OHA: 200, 4-OHA: 20; 100; 200; 400. 
Calibration curve. A six point calibration 
curve from 0 to 6 ng of 4-OHA was used, with 
4 ng of deuterated standard for each point. Each 
point was obtained by adding the appropriate 
quantities of 4-OHA and internal standard to a 
control plasma (200/~1) and performing the 
same purification and derivatization procedure 
of the plasma samples. The peak area ratios 
(PAR) were calculated using the signals at 359.2 
and 361.2 m/z for 4-OHA and its deuterated 
standard, respectively. Over this range of stan- 
dards the calibration curve was linear (corr. 
coeff, r ranged from 0.97 to 0.99). 
Sample preparation and purification. A sol- 
ution of the internal standard D2-4-OHA in 
ethanol (4 ng in 20 ~1) was added to the follow- 
ing volumes of plasma samples: 0.5ml for 
samples collected 0, 72, and 96 h after drug 
injection; 1.0 ml for samples collected 168, 240, 
and 336 h after drug injection; and 0.2 ml for 
samples collected 4, 8, 12, 24, 30, 36, 48, 54, and 
60 h after drug injection. These volumes were 
established, after an initial screening on a wide 
range curve (0-50 ng), to have samples contain- 
ing between 0 and 6 ng of 4-OHA. 0.18 ml of 
water were added to the 0.2 ml samples before 
adding the internal standard solution to prevent 
protein denaturation. After the addition of in- 
ternal standard, the plasma samples were equili- 
brated overnight at 4°C then purified using a 
solid phase extraction with Merck Extrelut 
columns (1 or 3 ml) eluted with hexane (10 or 
30ml). The eluted samples were evaporated 
under Nz at 40°C. 
Derivatization. Immediately after purifi- 
cation, derivatization was performed, treating 
the residues with 30/~1 of BSTFA for 1 h at 
room temperature to obtain the 4-TMS deriva- 
tive. The reaction mixtures were then evapor- 
ated under N 2 at 40°C and the residues dissolved 
in 40 #1 of heptane. 
GC-MS analysis. For sample analysis, the 
instrument was equipped with an HP1 column 
(12 m x 0.2 mm x 0.32/~m). 2/~1 of the heptane 
solutions of each sample were automatically 
injected in split-splitless mode (purge off time 
0.75min). The column temperature program 
was: 70°C for 1 min then 40°C/rain to 220°C, 
220°C for 0.5min then 10°C/min to 300°C, 
300°C for 5 min. In these conditions the reten- 
tion time of 4-OHA was 10.7 min. The two ions 
monitored by selected ion monitoring (SIM) 
were at 359.2 and 361.2 m/z for 4-OHA and 
D2-4-OHA, respectively, corresponding to the 
M- 15 fragments. 
Androgen and estrogen determination 
A new isotopic dilution GC/MS method for 
the simultaneous determination f testosterone 
(T), androstenedione (A) and E2 was developed 
with modifications of the reported method for 
the determination f E2 in plasma using isotope 
dilution mass spectrometry [9]. Because of the 
limited volume of the samples (2 ml) it was 
necessary to perform the determination f the 
three steroids imultaneously. Estrone determi- 
nation was not performed because we have been 
unable to find an appropriate deri7atization 
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procedure which will achieve accurate measure- 
ment of this steroid at very low concentrations 
in human plasma samples, and avoiding non- 
specific interferences. 
Internal standards. The following internal 
standards were used [7, 8], 16,16,1712H]3 testos- 
terone (D3-T), 7,712H]2 androstenedione (D2- 
A), 16,16,17[ 2H]3 estradiol (D3-E 2). 
Stock and working solutions. Stock solutions 
of analytes and internal standards were pre- 
pared in ethanol at a concentration f 1 #g/#l. 
Working solutions were prepared at a concen- 
tration of 10ng/#l, l ng/#l and 10pg/#l by 
diluting stock solutions. 
Calibration curves. Five point calibration 
curves were used in the following ranges: 
0-20ng for T, 0-4ng for A and 0-150pg for 
E2. For each point the following amounts of 
deuterated standards were added: 5 ng for T, 
1.25 ng for A and 150 pg for E 2. No plasma was 
used for these calibration curves. Each point of 
the calibration curve was derivatized using the 
same procedure used for the corresponding 
fraction of plasma samples, but without the 
purification procedure. The PAR were calcu- 
lated using the following signals: 580.4 and 
583.4m/z for T and D3-T, respectively; 432.3 
and 434.4 m/z for A and D2-A, respectively; and 
540.4 and 543.4 m/z for E 2 and D3-E2, respect- 
ively. 
Points fitted with polynomial curves of the 
second order for androgens, while there was a 
linear correlation for E2 (corr. coeff, r ranged 
from 0.98 to 0.99). 
Sample preparation and purification. A sol- 
ution containing D3-T and D2-A (20 #1, respect- 
ive concentrations: 250 and 62.5 pg/#l), and a 
solution of D3-E 2 (15 #l, 10 pg/#l) were added to 
2 ml plasma samples. 
Samples were equilibrated overnight at 
4°C. After equilibration a two steps purification 
procedure allowed us to separate androgens 
from estrogens and to perform a more suitable 
derivatization for each steroid. This pro- 
cedure includes a first purification step on 
Extrelut 3 columns followed by a chromato- 
graphic separation on Sephadex LH-20 
columns. 1 ml of distilled water was added to 
the equilibrated samples. Samples were then 
poured into Extrelut 3 columns and left aside 
for 30 min. 
Columns were eluted with 15ml of 
dichloromethane containing acetic acid 
(10ml/1). After evaporation under N 2 at 
40°C, dry residues were dissolved in 
200 #1 of dichloromethane-methanol-acetic 
acid (95:5:1, by vol) and applied to the top of 
Sephadex LH-20 columns (120 x 7mm) that 
had been swollen in the same eluent. The same 
eluent (150 #1) was used to wash the vial and the 
pipette and was then poured on the column, 
Fractions were collected with the following pat- 
tern: 1 ml discharged; 3ml collected (fraction 
containing T and A); 1.5 ml discharged (this 
fraction contained estrone); 3.5ml collected 
(fraction containing E2). Eluted fractions were 
evaporated under N2 at 40°C and dry residues 
were derivatized. 
Derivatization. (1) T and A were derivatized 
as pentafluoropropionic esters: 3,17-(PFP)2-T 
and 3-PFP-A, respectively. The derivatization 
was performed by dissolving the dry residues in 
100#1 of acetone and treating with 25 #1 of 
PFPA at 60°C for 1 h. The reaction mixture was 
evaporated todryness and the residue dissolved 
in 40 #1 of heptane. 
(2) E2 was derivatized as mixed trimethylsilyl 
ether-heptafluorobutyric ester (3-TMS- 17- 
HFB-HFB), using a multi-step rocedure [9]. 
The HFB ester 3,17-(HFB)2-E2 was first pre- 
pared with the same procedure used for the PFP 
esters of T and A, the reaction residue was then 
dissolved in 80#1 of methanol containing 
pyridine (100 ml/1) and left aside for 10 min at 
room temperature. After careful evaporation, 
the residue was treated with 75 #1 of BSTFA 
containing TMSC1 (50 ml/l) for 15 min at room 
temperature. The reaction mixture was evapor- 
ated under N2 at 40°C and the residue dissolved 
in 20 #1 of heptane. 
GC/MS analysis. For these samples the in- 
strument was equipped with an RLS 200 
column (15mx0.18mmx0.25#m).  3#1 of 
the heptane solutions were automatically in- 
jected in split-splitless mode (purge off time 
2.0m in). The column temperature program 
was: 70°C for 2m in then 40°C/min to 
240°C, 240°C for 2 min then 15°C/min to 300°C 
and 300°C for 10 min. In these conditions, the 
retention times were: 8.6 min for T, 9.0 min for 
A and 9.5 min for E2. The ions monitored in 
SIM mode were respectively: 580.3 and 
583.3 m/z for T and D3-T, 432.3 and 434.3 m/z 
for A and D2-A and 540.4 and 543.4 m/z for E 2 
and D3-E2. All these ions corresponded to the 
molecular ions. 
Sensitivity 
Sensitivity was evaluated using signal/noise 
ratios (S/N) calculated injecting derivatized 
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standards. Injection of 0.5 pg of 4-OHA pro- 
duced a S/N of 5/1; 10 pg of T produced a S/N 
of 28/1; 10 pg of A produced a S/N of 5/1 and 
10pg of E2 produced a S/N of 35/1. 
Recoveries 
The mean recovery for 4-OHA was 95% and 
ranged from 79 to 70% for T, A, and E2. 
Precision 
Precision for androgens and E2 was calculated 
by repeatedly analyzing 2 ml of male plasma 
(obtained from a local blood bank) on the same 
day and on different days. Results are reported 
in Table 1. 
Table 2. PAR in the same samples pre-incubated with E 2 
and treated according to the standard procedure (see text 
for details) 
Concentration Sample (PAR) Sample + E2(PAR ) 
Low 
Meas. 1 0.138 0.138 
Meas. 2 0.136 0.130 
Meas. 3 0.156 0.145 
Mean 0.143 0.138 
High 
Meas. I 0.443 0.448 
Meas. 2 0.436 0.457 
Meas. 3 0.472 0.426 
Mean 0.450 0.457 
Validation of the equilibration method for 4- 
OHA 
To validate the equilibration method for 4- 
OHA we compared two determinations of 4- 
OHA: the first one performed using the method 
described above and the second by adding, 
at the same time as the internal standard, a 
large excess of E2 (E2/4-OHA = 1000/1). This 
amount of E 2 was added in order to displace 
4-OHA from binding protein. If the time for 
equilibration of the standards with proteins is 
insufficient he PAR of the sample with E2 
would be higher than that of the sample 
without E2. The comparison was performed 
for two different concentrations of 4-OHA 
using two samples of the formulation of 
8.0#m particle size: the first at high 4-OHA 
concentration (volunteer 1 sample at 24 h) and 
the second at low concentration (volunteer 1 
sample at 96 h). Every determination was per- 
formed in triplicate. Results are summarized in
Table 2. There was no significant difference 
between the determinations made in the pres- 
ence or absence of E2. This experiment demon- 
strates that the 4-OHA determination method is 
not affected by errors due to 4-OHA binding to 
proteins. 
Table 1. Precision of androgens and E 2 determination 
Steroid T (ng/ml) A (ng/ml) E 2 (pg/ml) 
Intraassay 
Mean 2.17 0.49 24.76 
n 6 6 4 
SD 0.059 0.02 1.95 
CV% 2.7 4.1 7.8 
Interassay 
Mean 2.44 0.56 18.25 
n 6 5 5 
SD 0.212 0.11 5.3 
CV% 8.7 7 15 
RESULTS 
The values of 4-OHA determination for 
both formulations are summarized in Table 3 
and Fig. 1, respectively. The two profiles 
were analyzed using a three exponential 
model (SIPHAR ver.4, Simed; Creteille, 
France). For the 4.2~tm formulation the 
three half-life values were t~/2~= 7.35h; 
tl/2~ = 15.30 h and tl/2~ = 57.33 h. A.U.C. calcu- 
lated between 0 and 336 h was 1135.2 ng/ml/h, 
the total body clearance was 0.22 1/h. Cmax and 
tmax were 22.0 ng/ml and 27.6 h, respectively. 
Values for the same parameters with the 8.0/am 
formulation were: h/2~=6.80h; tl/2~----13.53h 
and h/2~ = 85.66 h; A.U.C. (0-336 h) = 
978.30ng/ml/h; total body clearance 0.241/h. 
Cmax and t~ax were 13.5ng/ml and 38h, 
respectively. 
The comparison between the two formu- 
lations was performed according to the 
Wilcoxon test for paired data. Even though the 
formulation with 4.2 pm particle size provided 
the higher 4-OHA plasma levels during the 48 h 
following the injection (the A.U.C. values be- 
tween 0 and 48 h were 744.1 and 448.08 ng/ml/h 
for the 4.2 and the 8.0 #m formulations, respect- 
ively), these values were not significatively 
different as were all the other kinetic par- 
ameters. With the formulation with 4.2 #m par- 
ticle size we studied the effects of 4-OHA using 
samples collected 0, 24, 48, 96 and 240 h after 
drug injection. Figure 2 shows E 2 and androgen 
mean plasma profiles. Table 4 summarizes re- 
sults for E2. A 250 mg dose of 4-OHA produced 
a 50% reduction in E 2 levels at 24h in all 
subjects except subject 2. This decrease was 
statistically significant according to the 
Wilcoxon test for paired data (P = 0.035). No 
significant correlation between 4-OHA and E2 
plasma levels at 24 h was found (r = 0.44). E2 
levels returned to the basal levels after 1 week. 
No significant changes in androgen levels were 
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Time h 0 4 8 12 24 30 36 48 54 60 72 96 168 240 336 
Particle size: 4.21an 
Vol. 1 0.0 20.3 21.7 12.3 20.6 22.9 27.9 9.8 6.4 4.8 2.9 1.5 0.2 0.1 - -  
Vol. 2 0.0 19.1 13.8 20.3 22.8 23.6 15.4 !1.2 6.1 4.4 3.7 1.2 0.2 - -  - -  
Vol. 3 0.0 20.6 20.1 19.7 30.6 26.4 17.8 12.6 9.3 6.7 4.8 1.5 0.3 0.2 - -  
Vol. 4 0,0 11.6 9.2 10.0 10.1 12.1 12.9 12.1 9.3 4.8 5.5 3.0 1.1 0.3 0.2 
Vol. 5 0,0 7.3 11.5 16.1 22.9 23.7 26.1 14.4 6.5 7.6 3.1 1.5 0.3 1.1 - -  
Vol. 6 0.0 10.8 9.6 7.8 7.4 8.6 6.5 6.7 5.2 3.2 4.3 3.2 2.1 1.3 i.1 
Mean 0.0 15.0 14.3 14.3 19.1 19.5 17.8 11.1 7.1 5.2 4.0 1.9 0.7 0.5 0.2 
SD 0.0 5.7 5.4 5.1 8.7 7.3 8.1 2.6 1.7 1.6 1.0 0.9 0.8 0.5 0.4 
CV% 0.0 40.0 40.0 30.0 40.0 40.0 40.0 20.0 20.0 30.0 20.0 90.0 110.0 100.0 200.0 
Particle size: 8.01~'n 
Vol. 1 0.0 16.0 16.1 7.8 14.7 I 1.5 9.6 11.3 8.5 5.9 4.0 ! .8 0.5 0.3 - -  
Vol. 2 0.0 4.1 7.7 7.2 5.5 5.1 6.9 9.4 6.0 6.7 5.9 4.0 1.7 i.0 0.8 
Vol. 3 0.0 5.8 4.2 3.8 5.8 4.7 5.6 8.9 5.5 6.3 4.8 3.4 1.6 1.3 1.0 
Vol. 4 0.0 7.4 11.4 7.9 17.7 14.9 6.9 4.7 4.2 2.9 2.6 1.5 1.2 0.8 0.6 
Vol. 5 0.0 8.2 10.5 13.6 11.5 13.8 13.5 16.7 14.0 11.3 8.9 3.8 1.5 0.3 - -  
Vol. 6 0.0 11.4 11.4 12.2 9.8 8.9 13.6 10.1 7.1 6.1 4.5 2.7 0.9 0.4 - -  
Mean 0.0 8.8 10.2 8.8 10.8 9.8 9.4 10.2 7.6 6.5 5.1 2.9 1.2 0.7 0.4 
SD 0.0 4.3 4.0 3.6 4.8 4.3 3.5 3.9 3.4 2.7 2.1 1.0 0.5 0.4 0.4 
CV% 0.0 50.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 30.0 40.0 60.0 1.0 
Measures below method sensitivity limit (10 pg/ml) were pointed out with ' - - ' ;  for statistical evaluation the above mentioned value was used. 
observed. Side effects were not observed with 
either formulation. 
DISCUSSION 
Several relevant observations stem from this 
study. First, the particle size does not seem to 
play an important role in determining the kin- 
etics of 4-OHA in human plasma. Second, after 
treatment with the formulation with 4.2#m 
particle size, 4-OHA in a 250 mg dose produced 
only a partial suppression of blood E 2 levels 
which returned to basal levels after 1 week. 
Moreover, A and T did not show any significant 
change. Finally, the effect of 4-OHA on E2 
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Fig. 2. Columns indicate the mean level and bars the standard error for the three steroids measured in 
blood. The analyses were performed on 6 subjects. The asterisk marks the data significantly different from 
the basal values according to the Wilcoxon test for paired data (P = 0.035). 
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Table 4. E 2 values (pg/ml) after a single 250 mg injection of 4-OHA 
(4.2 tim) 
Time h 0 24 48 96 240 Reduction % 
Vol. I 16.83 - -  - -  15.64 20.16 64.30 
Vol. 2 10.61 8.76 14.33 8.14 17.43 17.40 
Vol. 3 20.17 8.76 11.66 20.91 20.11 56.50 
Vol. 4 37.35 24.20 19.40 31.81 31.82 48.00 
Vol. 5 14.25 - -  10.63 10.94 25.75 57.80 
Vol. 6 15.34 7.14" 8.69 19.73 18.25 53.40 
Mean 19.09 10.14 11.78 17.86 22.25 49.70 
SD 8.65 6.39 4.26 7.69 5.03 
CV% 45 63 36 43 23 
Measures below method sensitivity limit (6 pg/ml) were pointed out 
with '--'. 6 pg/ml were assigned to volunteers 1 and 5 for 
statistical evaluation. Reduction % was evaluated comparing the 
lowest observed value with the basal level for each volunteer. The 
'*' indicates the value significantly different from the basal value 
(P = 0.035) according to the Wilcoxon test for paired data. 
peak of the maximum concentration of the 
inhibitor. 
The reduction of E2 levels (about 50%) ob- 
served after treatment with 4-OHA is similar to 
that reported by El Etreby et al. [10] in male 
volunteers using a different aromatase inhibitor 
with similar structure and mechanism ofaction. 
A possible explanation for this phenomenon 
could be the role played by other enzymatic 
activities involved in E 2 metabolism such as the 
sulfotransferase and sulfatase activities that are 
not affected by the drug [11]. This hypothesis  
reinforced by the absence of correlation between 
E2 suppression and 4-OHA circulating levels in 
our study. The role of sulfotransferase and 
sulfatase activities hould be more relevant in 
acute xperiments ( uch as those reported in the 
present paper) than during chronic adminis- 
tration when presumably the pool of estrogen 
sulfates is progressively decreased. 
The recovery of the basal estrogen levels after 
1 week found in our male subjects is again in 
agreement with E1 Etreby et al. [10]. On the 
other hand this phenomenon has not been ob- 
served in postmenopausal women treated with 
4-OHA in whom estrogen levels remained low 
after 1 week [12]. Because the blood production 
rates of aromatizable androgens (A + T) in men 
are at least four times higher than those of 
postmenopausal women [13, 14], we can reason- 
ably hypothesize that the quicker recovery of 
basal estrogen levels in men are due to the larger 
availability of aromatizable substrates. 
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